Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Licenses Exclusive Rights to Cold PCR

NEW YORK (GenomeWeb News) – Transgenomic has licensed exclusive rights to Cold-PCR technology from the Dana Farber Cancer Institute, the firm said Thursday.

The Omaha, Neb.-based pharmacogenomics firm said that it has exclusive rights to commercialize the technology for combined use with Sanger sequencing as well as for mitochondrial DNA analysis. Financial and further terms of the license were not disclosed.

Cold-PCR is a variation on standard PCR and "enriches mutations in DNA samples and is a much more sensitive technique for finding low level mutations in tissue and body fluids that are involved with a variety of diseases," said Transgenomic. The firm believes the technology will be able to detect cancer-related mutations that are present at a low level compared to normal DNA.

"We have long wanted a technology that would permit us to screen patients earlier in their development of cancer and we hope that Cold-PCR provides us the sensitivity and analytical accuracy to achieve this goal," Transgenomic CEO Craig Tuttle said in a statement.

Transgenomic had licensed an option on the Cold-PCR technology earlier this year. The firm said it used that option period to test the feasibility of the technology and developed laboratory improvements for its use.

"We demonstrated reproducible 30 - 50 fold enrichment of mutant cancer gene DNA, without needing any a-priori information on the position of the mutation," said Eric Kaldjian, CSO of Transgenomic.

"Combining Cold-PCR with Transgenomic's WAVE DHPLC and Surveyor Nuclease products may have the potential to detect one mutant copy of DNA out of as many as a thousand normal copies and the sensitivity is likely to keep improving," Kaldjian added. "This will be valuable in cancer-related mutation detection of free DNA in blood and body fluids and in producing a mutation profile of primary tumors to predict resistance to targeted therapies."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.